Use of sacubitril/valsartan in non‐compaction cardiomyopathy: a case report
Abstract The use of sacubitril/valsartan significantly reduces death or hospitalization in patients with ejection fraction < 40%. There is no study evaluating this drug effects in non‐compaction cardiomyopathy (NCCM) individuals. The aim of this article is to report a case of a patient with NCCM...
Saved in:
| Main Authors: | Marcely Gimenes Bonatto, Rodrigo Albanez, Vera Maria Cury Salemi, Lídia Zytynski Moura |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-06-01
|
| Series: | ESC Heart Failure |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/ehf2.12713 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Sacubitril/Valsartan attenuates progression of diabetic cardiomyopathy through immunomodulation properties: an opportunity to prevent progressive disease
by: Narainrit Karuna, et al.
Published: (2025-05-01) -
Expert Opinion on the Role of Sacubitril/Valsartan in the Management of Hypertension in India
by: Uday M. Jadhav, et al.
Published: (2024-11-01) -
Assessment of Left Ventricular Reverse Remodeling by Echocardiography After 90 Days of Sacubitril/Valsartan Therapy in Patients of Heart Failure with Reduced Ejection Fraction
by: Akshay Pawar, et al.
Published: (2024-12-01) -
Baseline left ventricular ejection fraction predicts the magnitude of improvement in patients taking sacubitril/valsartan
by: José-Manuel Rubio-Campal, et al.
Published: (2025-06-01) -
The use of sacubitril/valsartan in different forms of heart failure
by: Mohammad Abumayyaleh, et al.
Published: (2025-06-01)